Lipid Nanocarriers for Hyperproliferative Skin Diseases

Hyperproliferative skin diseases (HSD) are a group of diseases that include cancers, pre-cancerous lesions and diseases of unknown etiology that present different skin manifestations in terms of the degree and distribution of the injuries. Anti-proliferative agents used to treat these diseases are s...

Descripción completa

Detalles Bibliográficos
Autores: Souto, Eliana B., de Souza, Ana Luiza R., Dos Santos, Fernanda K., Sánchez-López, E. (Elena), Cano Fernández, Amanda, Zielinska, Aleksandra, Staszewski, Rafal, Karczewski, Jacek, Gremiao, Maria Palmira D, Chorilli, Marlus
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2021
País:España
Institución:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Repositorio:Recercat. Dipósit de la Recerca de Catalunya
OAI Identifier:oai:recercat.cat:2445/183722
Acceso en línea:https://hdl.handle.net/2445/183722
Access Level:acceso abierto
Palabra clave:Pell
Nanopartícules
Càncer de pell
Skin
Nanoparticles
Skin cancer
Descripción
Sumario:Hyperproliferative skin diseases (HSD) are a group of diseases that include cancers, pre-cancerous lesions and diseases of unknown etiology that present different skin manifestations in terms of the degree and distribution of the injuries. Anti-proliferative agents used to treat these diseases are so diverse, including 5-aminolevulinic acid, 5-fluorouracil, imiquimod, methotrexate, paclitaxel, podophyllotoxin, realgar, and corticosteroids in general. These drugs usually have low aqueous solubility, which consequently decreases skin permeation. Thus, their incorporation in lipid nanocarriers has been proposed with the main objective to increase the effectiveness of topical treatment and reduce side effects. This manuscript aims to describe the advantages of using lipid nanoparticles and liposomes that can be used to load diversity of chemically different drugs for the treatment of HSD. Keywords: lipid nanoparticles; liposomes; hyperproliferative skin diseases; antiproliferative drugs; skin cancer